In an exploratory secondary analysis of the GAP70+ trial (706 adults ≥70 years with advanced cancer), 8.4% prioritised survival and 71.7% quality of life; preference was not associated with treatment changes, grade 3-5 toxicity, hospitalisation or survival.
Secondary analysisn = 706
Richardson et al. Outcomes of Older Adults With Advanced Cancer Who Prefer Quality of Life vs Prolonging Survival: A Secondary Analysis of the GAP70+ Cluster Randomized Clinical Trial